|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
GEIGY Pharmaceuticals |
|---|---|
| Information provided by: | National Institute of Mental Health (NIMH) |
| ClinicalTrials.gov Identifier: | NCT00000390 |
Purpose
To test the effectiveness treating AIDS related depression with imipramine hydrochloride.
Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status.
This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.
| Condition | Intervention | Phase |
|---|---|---|
|
Depression |
Drug: Imipramine hydrochloride |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Placebo Control |
To test the effectiveness treating AIDS related depression with imipramine hydrochloride.
Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status.
This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations More Information
| Study ID Numbers: | 87-DEP |
| Study First Received: | January 17, 2000 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000390 |
| Health Authority: | Unspecified |
|
Adult Acquired Immunodeficiency Syndrome Depression Female Human Imipramine |
Male Middle Age Acquired Immunodeficiency Syndrome -- *complications Depression -- *drug therapy Depression -- etiology Imipramine -- *therapeutic use |
|
Imipramine Depression Mental Disorders HIV Infections Acquired Immunodeficiency Syndrome |
Mood Disorders Depressive Disorder Immunologic Deficiency Syndromes Behavioral Symptoms |
|
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Adrenergic Uptake Inhibitors Therapeutic Uses |
Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Agents Pharmacologic Actions Antidepressive Agents Antidepressive Agents, Tricyclic |
